Streuli Pharma AG Issues Recall Of Vitamin D3 Due To Potential Glass Contamination
Streuli Pharma AG, based in Uznach, has initiated a precautionary recall of several batches of its Vitamin D3 product, Vitamin D3 Streuli Prophylax, due to concerns of potential glass fragments being present within the pipette of the product. This announcement was made following the identification of a quality defect associated with certain batches, prompting immediate action to safeguard consumer health.
According to the Federal Office of Consumer Affairs, there are six specific batches involved: 2330523BA, 2430110BA, 2430135AA, 2430136AA, 2430137AA, and 2430241AA. Consumers are advised to stop using the affected products and return them to their pharmacy, doctor's office, or drugstore as soon as possible.
This recall only pertains to the specified batches and not to the entire product line. The quality issue was detected within the glass pipettes used for the delivery of the Vitamin D3 solution, raising concerns about possible contamination, which could result in health risks for consumers.
Swissmedic, the Swiss Agency for Therapeutic Products, has endorsed Streuli's decision to remove these batches from the market as part of their commitment to ensuring the safety and integrity of medicinal products. Officials have confirmed there are no reported instances of adverse effects associated with the recalls as of this time. Nevertheless, they emphasized the importance of consumer vigilance and adherence to the recall instructions.
Vitamin D3 plays a significant role in calcium absorption and is often recommended as part of dietary supplements, especially for individuals at risk of deficiency due to lack of sunlight exposure or other health conditions. It's widely used across various demographics, with specific dosages recommended for infants, children, and adults. For infants and small children, typical dosages range from 400 to 600 International Units (IU) per day, though adults may require higher doses based on individual needs.
Experts note it is important consumers consult health professionals before taking vitamin D3 supplements, particularly if they are already using other vitamin-fortified products. This consultation can help prevent potential overdoses, as excessive vitamin D can lead to health complications.
Streuli Pharma AG has urged any consumers who purchased Vitamin D3 Streuli Prophylax from the affected batches to contact their customer service department for more information and guidance. Customers can reach them via phone at 055 285 92 92 or through email at [email protected].
Aside from potential health risks, recalls like this can impact consumer trust and the larger pharmaceutical industry, drawing attention to manufacturing practices and quality control measures. The swift action taken by Streuli Pharma AG may help mitigate potential issues and reaffirm their commitment to consumer safety.
Consumers are encouraged to stay informed through reputable news sources and health information platforms about the status of such recalls and any updates from health authorities. This is especially important as recalls can be part of broader trends focusing on quality assurance within the pharmaceutical sector.
Consumers should watch for additional information from Swissmedic and other regulatory bodies for any updates related to the recall, including possible investigations or findings from the quality assessment processes involved.